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ABSTRACT: Introduction: Immune activation has been impli-
cated in progression of amytrophic lateral sclerosis (ALS). Oral fin-
golimod reduces circulating lymphocytes. The objective of this
phase IIa, randomized, controlled trial was to test the short-term
safety, tolerability, and target engagement of fingolimod in ALS.
Methods: Randomization was 2:1 (fingolimod:placebo). Treat-
ment duration was 4 weeks. Primary outcomes were safety and
tolerability. Secondary outcomes included circulating lympho-
cytes and whole-blood gene expression. Results: Thirty partici-
pants were randomized; 28 were administered a drug
(fingolimod 18, placebo 10). No serious adverse events
occurred. Adverse events were similar by treatment arm, as
was study discontinuation (2 fingolimod vs. 0 placebo, with no
statistical difference). Forced expiratory volume in 1 second
(FEV1) and FEV1/slow vital capacity changes were similar in
the fingolimod and placebo arms. Circulating lymphocytes
decreased significantly in the fingolimod arm (P<0.001). Nine
immune-related genes were significantly downregulated in the
fingolimod arm, including forkhead box P3 (P<0.001) and
CD40 ligand (P5 0.003). Discussion: Fingolimod is safe and
well-tolerated and can reduce circulating lymphocytes in ALS
patients.
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Amyotrophic lateral sclerosis (ALS) is a degenera-
tive disorder primarily affecting motor neurons,
which results in progressive wasting and paralysis
of voluntary muscles.1 Fifty percent of ALS patients
die within 3 years of onset of symptoms and 90%
within 10 years.2,3 Riluzole, the only U.S. Food and
Drug Administration (FDA)-approved disease-
modifying drug to treat ALS, demonstrates a mod-
est survival benefit.4,5 An urgent need for novel
treatments is clear.
Neuroinflammation is increasingly implicated in
ALS pathogenesis.6–11 Mouse models of ALS show
that activation of microglia and influx of T lympho-
cytes into the central nervous system (CNS) occur
early in the disease or before symptom onset6,11,12
and colocalize with disease symptoms.13 Human
postmortem tissue analysis shows lymphocytic infil-
trates in the CNS,14 positron emission tomography
(PET) imaging reveals increased microglial activa-
tion,9,10 and analysis of circulating monocytes shows
Additional supporting information can be found in the online version of this
article.
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activation.11,15–18 The interplay among monocytes,
T cells, and microglia facilitates a pro-inflammatory
state, suggesting that targeted reduction of inflam-
mation could alter ALS progression.
Although immune activation appears to be
important, trials of broadly active immunosuppres-
sants have failed to show benefit,19–22 perhaps
because these agents suppress all immune func-
tion. However, although one part of the immune
response activates neuroinflammation, another
part, namely the regulatory T-cell population,
holds neuroinflammation in check.7 A decrease in
number and function of regulatory T cells corre-
lates with faster disease progression, and increased
numbers and function of regulatory T cells corre-
late with slowing of progression.23–25 Regulatory
T-cell function can be measured using expression
of forkhead box P3 (FOXP3), and decreased
FOXP3 expression also correlates with more
rapid disease progression.25 Thus, in ALS, more
focused immune modulation that spares regulatory
immune function may be required. In a screen of
immune modulators at the ALS Therapy Develop-
ment Institute (ALSTDI), anti-CD40 ligand anti-
body11 and fingolimod improved survival in
superoxide dismutase 1 (SOD1G93A) mice. Further-
more, an independent study demonstrated the
benefit of fingolimod in SOD1 mice.26
Fingolimod is an immunomodulatory drug that
antagonizes the sphingosine 1-phosphate (S1P)
receptors (primarily S1P1), blocking egress of lym-
phocytes from secondary lymph organs and reduc-
ing circulating lymphocytes. Thus, it provides a
more focused immune modulation than the broad
immunosuppressive regimens previously tested in
ALS. It has been used in neuroinflammatory con-
ditions and is an FDA-approved therapy for multi-
ple sclerosis (MS). At the time of this study, there
was concern about the short-term safety profile of
fingolimod, and this needed to be explored before
long-term testing in ALS patients. Known side
effects include first-dose bradycardia, which peaks
approximately 6 hours after administration, and
small and clinically insignificant decreases in
forced expiratory volume in 1 second (FEV1),
beginning within 1 month of drug initiation. Mac-
ular edema generally occurs after at least 3 months
of administration, and progressive multifocal leu-
koencephalopathy has been reported in patients
on the drug for many months, particularly those
with a history of taking other immunosuppressive
therapies.
The primary objective of this study was to deter-
mine the short-term safety and tolerability of oral
administration of the FDA-approved fingolimod
dose of 0.5mg/day for 4 weeks, relative to placebo,
in a phase IIa, randomized, placebo-controlled,
blinded trial. Secondary objectives were to quantify
the effect of fingolimod on circulating lymphocyte
populations in those with ALS, to confirm this
pharmacodynamic marker of target engagement,
and to evaluate the effect of fingolimod on gene
expression profiles in whole blood to determine
whether it may be used as a pharmacodynamic
marker and provide further biological rationale for
future studies of fingolimod use for ALS patients.
METHODS
This study was coordinated through the Massachusetts
General Hospital (MGH) Neurological Clinical Research
Institute (NCRI), and included 4 participating sites: Univer-
sity of California, Irvine; MGH; Augusta University Medical
Center; and Methodist University. The local institutional
review board at each site approved the study. Whole-blood
RNA analysis was performed at the ALSTDI. The trial has
been registered at clinicaltrials.gov (NCT01786174).
Participant Selection Criteria. At screening, eligible par-
ticipants had a diagnosis of possible, probable laboratory-
supported, probable, or definite ALS, according to El Esco-
rial criteria27; a slow vital capacity (SVC) of 65% of the pre-
dicted normal value for height, age, and gender; a symptom
duration of <2 years; an ability to swallow capsules; and were
either not on riluzole or on a stable dose for 30 days.
Exclusion criteria included use of mechanical ventilation or
presence of a feeding tube, previous use of fingolimod, preg-
nancy, exposure to investigational agents within 30 days of
screening, lymphopenia, active autoimmune disease or infec-
tion, stroke or myocardial infarction within the last 6 months,
atrioventricular (AV) block, bradycardia or prolonged QTc
(>450 ms for women,> 430 ms for men) by history or on
electrocardiogram (ECG), history of macular edema or uve-
itis, or clinically significant abnormal safety laboratory values.
Potential participants were also excluded for concurrent
treatment with immunosuppressants, class Ia or III antiar-
rhythmic medications, beta-blockers, calcium-channel block-
ers, or QT-prolonging medications.
Randomization. A permuted-block randomization sched-
ule was prepared by a statistician at the MGH Biostatistics
Center, stratified by site. Participants were randomly
assigned in a 2:1 ratio to oral fingolimod 0.5mg/day or
matching placebo.
Study Overview. Participants signed an informed con-
sent form before screening. Medical history, detailed ALS
history, physical and neurological examinations, medication
review, vital capacity testing, administration of the ALS
Functional Rating Scale—Revised (ALSFRS-R), vital signs,
ECG, and laboratory tests were performed to determine
eligibility. For eligible participants, the baseline visit (day
0), when study drug was initiated, occurred within 21 days
of screening. Follow-up visits occurred at day 1, week 2, and
week 4. A final phone call occurred 4 weeks after partici-
pants stopped study drug (week 8) (Fig. 1).
Study Drug. Because extensive dosing studies of fingoli-
mod had already been completed, the FDA-approved dose
was used for this trial. The first dose was administered in
the clinic at the baseline visit and the remaining supply for
the study was dispensed in blister packs. Participants were
instructed to take the study drug daily and filled out a drug
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diary for the duration of the study. They remained on study
drug for 4 weeks.
Study Procedures. At the baseline visit, participants were
monitored on-site for 8 hours with hourly vital signs and an
ECG both before and after administration of drug. For
safety, participants were not discharged from the study visit
with symptomatic bradycardia or if their final heart rate
measurement was the lowest of the day. Participants
returned the day after the baseline visit (day 1) for evalua-
tion of vital signs and for general health status.
Clinical measurements at all visits included SVC, FEV1,
ALSFRS-R, and visual acuity using a Snellen chart.
Safety labs were collected at the baseline, week 2, and
week 4 visits and analyzed at a central lab (University of
Rochester, Rochester, New York). Safety labs were moni-
tored by the site investigator and available to the study prin-
cipal investigator for safety review. The lymphocyte counts
in peripheral blood acted as a marker of peripheral target
engagement. Therefore, after initiation of study drug, study
staff at the site and coordination center were blinded to
lymphocyte count. An independent reviewer monitored lym-
phocyte counts to maintain blinding of study staff while
ensuring safe follow-up. The independent reviewer was to
notify the site investigator if absolute lymphocyte counts
dropped to <200/ll. Counts< 500/ll were tolerated with-
out stopping the drug.
For whole-blood RNA analysis, blood was collected into
3 RNase-free PAXgene tubes at the baseline and week 4 vis-
its. The blood was shipped ambient overnight to a central
lab (ALSTDI, Cambridge, Massachusetts) for RNA extrac-
tion using a blood total RNA extraction kit (Agencourt
RNAdvance; Beckman Coulter, Porterville, California).
Gene expression analysis was performed at the ALSTDI at
the conclusion of the study, after all samples had been col-
lected, but before unblinding.
Whole-Blood Gene Expression Analysis. After RNA
extraction, 2 gene expression arrays were run to measure
gene expression levels by quantitative polymerase chain
reaction. A human immune panel (Applied Biosystems Taq-
Man Array; Thermo Fisher Scientific, Waltham, Massachu-
setts) was used to measure 90 immune-related genes plus 6
housekeeping genes. A second custom panel containing
FOXP3 plus 4 housekeeping genes was used to measure
FOXP3 gene expression. Gene expression was normalized
following the geNorm methodology28 with levels for
18S, beta-actin (ACTB), glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH), and phosphoglycerate kinase 1
(PGK1) used to normalize the pre-configured panel and
ACTB, GADPH, and PGK1 used to normalize FOXP3
expression levels. Mean log-transformed fold-change in rela-
tive expression from baseline to week 4 was compared
between arms by the 2-sample Student t-test for each gene.
For purposes of this exploratory analysis, differences with a
nominal P< 0.01 were considered statistically significant.
Statistical Analysis. Safety was assessed with respect to
incidence of bradycardia, general adverse events (AEs), lab
abnormalities, and changes in FEV1 and FEV1/SVC. AEs
were coded to preferred terms from the MedDRA library
(version 16.1) and compared using the Fisher exact test.
Heart rate immediately posttreatment (days 0 and 1) was
analyzed in repeated-measures analysis of variance models
to detect treatment-dependent bradycardia, an AE of partic-
ular interest. Intolerance for an individual participant was
defined as discontinuing study drug or dropping out from
the study before 4 weeks after drug initiation at the baseline
visit. Fingolimod was considered tolerable if the rate of
intolerance was <40% with 80% confidence; that is, an
upper 1-tailed 80% confidence bound on the proportion of
fingolimod-treated participants determined intolerant that
was <40%.
Target engagement was assessed by analyzing circulating
lymphocyte counts. Changes in ALSFRS-R and SVC were
monitored, but the trial did not have power to test efficacy.
Lymphocyte counts, ALSFRS-R, and pulmonary function
testing (PFT) measurements were analyzed in shared-
baseline, random-slope mixed models. Models for ALSFRS-
R and PFT measurements adjusted for bulbar onset and
FIGURE 1. Trial design. [Color figure can be viewed at wileyonlinelibrary.com]
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baseline SVC and their interactions with time. Four-week
changes from baseline and their 95% confidence intervals
were estimated using linear contrasts. All participants who
initiated treatment were analyzed.
Power Calculations. Tolerability. Assuming 20 par-
ticipants receiving active study drug, observing 5 or fewer
intolerant participants would satisfy the criterion for judging
fingolimod tolerable. The study had 80% power to declare
fingolimod tolerable if the expected rate of intolerance was
20%.
Safety. Using the calculation power5 1 – (1 – P)n,
where P is probability of an event and n is the number of
subjects in a treatment arm, and assuming 20 participants
in the fingolimod arm, the study had >80% power to detect
any adverse event caused by fingolimod for which the
expected frequency was 8%.
RESULTS
Thirty-nine subjects were screened for this
trial, 30 were randomized, and 28 initiated treat-
ment and completed the study (Fig. 2). Two sub-
jects were randomized but did not receive study
drug: 1 subject developed a urinary tract infection
and decided to withdraw from the study; another
subject was found to have a prolonged QTc inter-
val at the baseline visit and was not administered
study drug. Under the pre-specified modified
intention-to-treat analysis plan, data from these 2
subjects were not included in the final analysis.
One subject on fingolimod discontinued treat-
ment after 2 weeks due to fatigue and progressive
weakness interfering with trial commitments.
Another subject on fingolimod discontinued the
study drug after 2 weeks due to prolonged QTc.
Both subjects continued to be followed off study
drug and were included in the intent-to-treat anal-
ysis as planned.
Treatment arms were similar on baseline charac-
teristics. Bulbar onset was slightly overrepresented
in the placebo arm and SVC was slightly higher in
the fingolimod arm, but the differences were not
statistically significant. Although the differences
between bulbar onset and baseline SVC were purely
due to chance, their magnitude was potentially
meaningful, so analyses of ALSFRS-R, FEV1, and
SVC were adjusted for these variables, as described
in the Methods section (Table 1).
Two major protocol violations related to eligi-
bility occurred during the trial and were recog-
nized in retrospect. Two participants were
randomized despite being on QT-prolonging medi-
cations (1 on sertraline and 1 on amitriptyline).
Both subjects completed the protocol.
Safety and Tolerability. The trial met its primary
endpoints for short-term safety and tolerability.
Eighty-nine percent (16 of 18) of the participants
in the fingolimod arm and 100% (10 of 10) of
those in the placebo arm completed the study on
study drug (refer to Table S1 in the Supplemen-
tary Material, available online).
There were no serious adverse events (SAEs)
during the trial. AEs occurring in at least 2 partici-
pants in the active arm are summarized in Table 2
by MedDRA preferred term; none were signifi-
cantly more common in the fingolimod arm. Out-
side of the expected reductions in lymphocyte
counts in participants receiving fingolimod, there
were no clinically significant abnormalities on rou-
tine blood counts, chemistries, or urinalysis during
the course of the study. Alkaline phosphatase
increased by 8.4 U/L from baseline to week 4 in
the fingolimod arm (vs. a decline of 2.8 U/L in
the placebo arm, P5 0.02). Liver function tests did
not change significantly in the fingolimod arm or
relative to the placebo arm.
FIGURE 2. CONSORT diagram. Participant enrollment, intervention allocation, and follow-up for the trial.
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As noted, fingolimod is known to induce heart
rate slowing in the hours after the first dose. In
the hours after the first dose, participants in the
fingolimod arm had a greater mean heart rate
(HR) slowing than participants in the placebo
arm, with a nadir at 5 hours (Fig. 3). Three
participants were noted to have transient brady-
cardia, but there were no clinical symptoms asso-
ciated with the heart rate slowing. By 24 hours
after the first dose, the mean HR change did not
differ between the fingolimod arm and the pla-
cebo arm (Fig. 3). Significant heart rate slowing
was not seen in the fingolimod arm at 2 or 4
weeks.
Mean FEV1 was 83% of predicted normal over-
all at baseline and did not differ significantly
between the arms. FEV1 declined modestly in both
arms over the course of the study but did not
decline more rapidly in the fingolimod arm
(Fig. 4A). SVC and FEV1/SVC ratio also did not
decline more rapidly in the fingolimod arm (Fig.
4B). Finally, rate of decline in ALSFRS-R total
score did not differ significantly between arms
(Fig. 4C).
Table 1. Baseline characteristics of study participants
Overall Fingolimod Placebo P-value
Number 30 18 10
Male gender 53.6% 55.6% 50.0% 1.0
White race 92.9% 100% 80% 0.12
Age (years) 55.96 9.1 56.46 8.0 55.16 11.3 0.72
Bulbar onset 21.4% 11.1% 40.0% 0.15
Riluzole use 60.7% 61.1% 60.0% 1.0
SVC (percent predicted) 89.26 20.0 92.86 18.5 82.86 21.9 0.19
FEV1 (percent predicted) 82.86 20.6 83.56 16.1 81.46 27.9 0.80
FEV1/SVC 75.36 14.5 73.36 10.0 78.86 20.4 0.32
ALSFRS-R 38.56 4.7 38.86 4.1 37.96 5.8 0.63
Months since symptom onset 13.56 5.3 12.66 4.8 15.06 6.2 0.25
Months since diagnosis 5.76 3.9 5.56 3.9 6.06 4.0 0.73
Diagnostic delay (months) 7.86 4.2 7.26 4.2 9.06 4.3 0.27
EEC definite 53.6% 61.1% 40.0% 0.27
EEC probable 32.1% 33.3% 30.0%
EEC probable lab-supported 14.3% 5.6% 30.0%
Lymphocyte count (109/L) 1.866 0.68 1.866 0.74 1.866 0.60 0.98
Resting HR (bpm) 74.66 11.4 73.36 11.0 76.96 12.4 0.41
BMI (kg/m2) 26.26 3.7 26.16 3.0 26.36 4.9 0.88
Data are presented as either percentages or mean (6 standard dviation). VC and FEV1 are presented as percent of predicted values. Lymphocyte counts
are measured as 109/L. Diagnostic delay represents the time from symptom onset to diagnosis. ALSFRS-R, ALS Functional Rating Scale—Revised; BMI,
body mass index (measured in kg/m2); EEC, El Escorial criteria; FEV1, forced expiratory volume in the first second; HR, heart rate (measured in beats per
minute); SVC, slow vital capacity.






Asymptomatic bradycardia 17% 0% 0.53
Fatigue 22% 30% 0.67
Fall 33% 10% 0.36
Muscular weakness 17% 20% >0.99
Headache 22% 20% >0.99
Cough 11% 0% 0.52
No adverse events were significantly more common in the fingolimod
arm than the placebo arm. Adverse events occurring in at least 2 sub-
jects in the treatment arm are shown.
FIGURE 3. Hourly measurement of heart rate (HR) at the base-
line visit in the active arm and placebo arm. Participants in the
fingolimod arm had a mean HR decline of –12.8 beats per
minute (bpm) (–7.0 to –18.7 bpm) from pre-dose to post-dose
nadir, which occurred at 5 hours, on average. This change dif-
fered from placebo significantly (P50.002). By 24 hours after
the first dose, HR had largely returned to baseline and there
was no statistically significant difference in HR between the 2
arms (P5 0.10) [the mean HR change at 24 hours (relative to
baseline) was –4.5 bpm (128 to –11.7 bpm) in the fingolimod
arm vs.13.4 bpm (112.2 to –5.5 bpm) in the placebo arm].
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Lymphocyte Counts. Total lymphocyte counts in
circulation declined from baseline in the fingoli-
mod arm (Fig. 5A). The ratio of CD41 (helper) to
CD81 (suppressor) lymphocytes in circulation
declined, suggesting that CD41 lymphocytes were
more effectively sequestered than CD81 lympho-
cytes (Fig. 5B). B-cells (CD19) decreased (week 4:
–88% fingolimod vs.1 1% placebo, P< 0.001) as
expected. Natural killer cells (CD161CD56) were
the only lymphocyte subset that did not decrease.
Lymphocyte count did not drop below 200/ml
in any of the participants, thus the independent
monitor did not ever need to report counts to
study sites, and no unblinding occurred.
Whole-Blood Gene Expression Profiling. Whole-
blood gene expression analysis investigated 91
immune-related RNAs (refer to Table S2 in Sup-
plementary Material online) at baseline and week
4. Of these, 9 were significantly downregulated in
the fingolimod arm relative to placebo after 4
weeks of treatment, including FOXP3 (Table 3).
DISCUSSION
The trial met its primary endpoint, demonstrat-
ing short-term safety and tolerability of oral fingoli-
mod 0.5mg/day in ALS patients. Given that the
short-term safety profile had caused concern in
early trials in multiple sclerosis, and hints of a del-
eterious effect on FEV1 had been reported, this
hurdle needed to be cleared before consideration
of fingolimod for further study in those with ALS.
Circulating lymphocyte counts acted as a reli-
able peripheral biomarker of target engagement.
FIGURE 4. FEV1, SVC, and ALSFRS-R at the baseline, week 2, and week 4 visits in the active and placebo arms. (A) FEV1 did not
decline more rapidly in the fingolimod arm (4-week change from baseline: fingolimod –1.6% vs. placebo –3.8%; P5 0.57). (B) Fingoli-
mod did not significantly affect rate of progression as measured by SVC, nor were clinically relevant benefits or harm ruled out in this
small, short-duration trial. (C) Fingolimod did not significantly affect rate of progression as measured by ALSFRS-R (difference in
8-week change from baseline: –0.4; 95% confidence interval –2.1 to 1.4; P5 0.68), nor were clinically relevant benefits or harm ruled
out in this small, short-duration trial.
FIGURE 5. Total lymphocyte counts and lymphocyte subpopulations counts at baseline, week 2, and week 4 visits in the active and
placebo arms. (A) Lymphocytes were dramatically reduced in the fingolimod arm relative to the placebo arm (week 2: –67% fingolimod
vs. –1% placebo; week 4: –72% fingolimod vs.1 4% placebo; P<0.001 for both). (B) T-helper lymphocytes were more affected than
T suppressors (week 4: –75% fingolimod vs.1 3% placebo; P<0.001).
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Whole-blood gene expression profiling demon-
strated a focused reduction of immune-related
gene expression, including FoxP3 and CD40
ligand, both implicated in disease pathogenesis.
The well-described first-dose bradycardia of fin-
golimod seen in this study mimicked that previ-
ously described in patients with MS.29,30 The
current FDA recommendation for 6-hour observa-
tion seems to be appropriate in people with ALS.
To avoid unblinding effects of lymphocyte
changes, we used an independent lymphocyte
reviewer. The first-dose bradycardia could poten-
tially have had an unblinding effect, although in
this trial the risk was somewhat attenuated by sub-
stantial interparticipant variability in the heart rate
changes. Future studies should incorporate surveys
of participants and study staff to understand treat-
ment assignment perceptions and quantify the
unblinding effect. The incorporation of unblinded
team members to monitor vital signs at the first
visit could be considered to maintain blinding.
In multiple sclerosis, fingolimod produced a
clinically insignificant decrease in FEV1 within 1
month of therapy and was stable thereafter.29 Like-
wise, there was no statistically significant reduction
in FEV1 or FEV1/SVC in those with ALS.
The preferential sequestration of CD41 lympho-
cytes over CD81 lymphocytes is notable in light of
data suggesting slower disease progression in ALS
patients with higher regulatory T-lymphocyte counts
(CD41/CD171). One limitation of our pilot study
is that it did not include direct quantification of
CD171 cells, an aspect of the immune response
that should be included in a follow-up study.
Our exploratory analysis of whole-blood gene
expression provides evidence that fingolimod has a
focused effect on immune function—only a small
proportion of immune-related genes showed a sig-
nificantly different change in the fingolimod arm.
The changes we did see may provide insight into
the relevant action of the drug in ALS. For exam-
ple, the reductions in costimulatory pathway genes
(CD40 ligand and CD28) point to a beneficial
effect on 1 pro-inflammatory pathway thought to
be relevant in ALS. Previous studies in preclinical
models of ALS suggest that blocking the costimula-
tory pathway may provide therapeutic benefit in
ALS patients.11 FoxP3 expression in whole blood
may be a good proxy for regulatory T-cell activity.
Given the correlation between increased regulatory
T-cell activity and slow disease progression, an
absolute reduction of FoxP3 in the absence of
other immune-related gene changes may be cause
for caution. In this case, the reduction in FoxP3
occurred in the context of a more elaborate
immune modulation—for example, a reduction in
total circulating lymphocytes—and must be inter-
preted with caution.
In this small trial, the addition of biomarkers
to track inflammation in the CNS was impractical.
The variability of cerebrospinal fluid cytokines,
such as monocyte chemoattractant protein-1,
would have meant that we would have had limited
power to detect differences between the arms; the
added complexity and expense of lumbar puncture
would have been difficult to justify. Likewise, data
regarding the peripheral benzodiazepine receptor
(PBR28) PET ligand were limited, thus the addi-
tional complexity and high costs of PET were diffi-
cult to justify. In follow-up studies, these markers
of inflammation in the CNS could be considered
to supplement efficacy measures, although power
calculations would be prudent to weigh potential
benefit against known measurement variability.
The lack of an observable treatment effect of
fingolimod on ALSFRS-R or SVC in this study is
uninformative—the trial did not have statistical
power to detect such a change. A larger study is
Table 3. Immune-related genes with significantly different changes from baseline to week 4 in the fingolimod arm relative to the placebo
arm






















BCL2 0.282 0.076 0.271 0.251 0.360 1.436 0.189 <0.001
CCR4 0.336 0.080 0.024 0.289 0.375 1.295 0.183 <0.001
CCR7 0.226 0.004 0.016 0.281 0.264 0.938 0.017 <0.001
CD3E 0.169 0.042 0.246 0.129 0.142 1.097 0.224 <0.001
CD8A 0.109 0.044 0.406 0.076 0.083 1.085 0.374 0.004
CD19 0.228 0.021 0.093 0.184 0.263 1.428 0.065 <0.001
CD28 0.352 0.025 0.072 0.231 0.322 1.393 0.051 <0.001
CD40LG 0.229 0.043 0.188 0.261 0.250 0.995 0.189 0.003
FOXP3 0.422 0.080 0.189 0.426 0.411 0.965 0.196 <0.001
Of the 91 immune-related genes explored in whole blood using PCR analysis, 9 were significantly reduced from baseline to week 4 in the fingolimod arm
relative to the placebo arm. CD40LG, cluster of differentiation 40 ligand.
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needed to evaluate clinical efficacy of oral fingoli-
mod for the treatment of those with ALS.
Based on the rapid and robust decline in circu-
lating lymphocytes and data from other studies, a
0.5-mg/day dose of fingolimod in an ALS patient
may be too high. Given that the goal of fingolimod
therapy in ALS is immune modulation, a higher-
than-optimal dose may tip the balance from
immune modulation toward overt (and potentially
counterproductive) immune suppression. In preclin-
ical studies of fingolimod in SOD1G93A mice at the
ALSTDI, a substantially lower daily dose of
0.32mg/kg had a maximal effect on lymphocyte
depletion in the circulation by 14 days, and fingoli-
mod accumulated in the spinal cord tissue over
time (unpublished observations). Similar observa-
tions were noted in the FDA new drug application
review of fingolimod for MS, where a daily dose of
0.5mg was higher than the observed half-minimal
inhibitory concentration (0.345 ng/ml).31 Such an
observation could suggest that a dose-optimization
study would be warranted before further trials of
fingolimod in ALS. A follow-up study in ALS could
assess efficacy, directly quantify regulatory T-cell
and monocyte populations, measure gene expres-
sion changes within specific cell populations, and
possibly evaluate imaging-based markers of
neuroinflammation.
Data suggesting a role for immune dysregula-
tion in ALS are accumulating, and novel therapies
aimed at suppressing the immune system entirely
have not yet been successful at slowing disease pro-
gression. Fingolimod, an immune modulator,
holds promise as a means to manipulate the
immune system, creating a less inflammatory state.
In this study we have demonstrated short-term
safety and tolerability in this population, target
engagement, and broad immune system function
changes by whole-blood gene expression.
The authors thank Dr. Merit Cudkowicz for help with study design
and guidance throughout the conduct of the study. Both study
drug and placebo were provided by Novartis Pharmaceuticals.
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